Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients
De Forni et al., PLoS ONE, doi:10.1371/journal.pone.0276751 (In Vitro)
De Forni et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, PLoS ONE, doi:10.1371/journal.pone.0276751 (In Vitro)
Nov 2022   Source   PDF  
  All Studies   Meta
Vero E6 In Vitro study showing remdesivir and ivermectin or azithromycin to be highly synergistic with 4-13 times lower concentration required for 100% inhibition.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
3 In Vitro studies support the efficacy of remdesivir [De Forni, Delandre, Jeffreys].
De Forni et al., 10 Nov 2022, peer-reviewed, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: PLOS ONE RESEARCH ARTICLE Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients Davide De Forni1☯, Barbara Poddesu1☯, Giulia Cugia1, James Chafouleas1, Julianna Lisziewicz2, Franco Lori1,2* 1 ViroStatics s.r.l., Tramariglio, Italy, 2 Research Institute for Genetic and Human Therapy, Colorado Springs, CO, United States of America a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: De Forni D, Poddesu B, Cugia G, Chafouleas J, Lisziewicz J, Lori F (2022) Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. PLoS ONE 17(11): e0276751. https://doi. org/10.1371/journal.pone.0276751 Editor: Hiroj Bagde, Rama Dental College and Hospital and Research Centre, INDIA Received: March 22, 2022 Accepted: October 12, 2022 Published: November 10, 2022 Copyright: © 2022 De Forni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: Funds were collected by the not-for-profit Research Institute for Genetic and Human Therapy (RIGHT) through a crowdfunding campaign named GoFundMe "COVID-19: ora serve una Cura" ( RIGHT acted as the sponsor of the study and, as institution, had no role in the writing of the manuscript or the decision ☯ These authors contributed equally to this work. * Abstract Despite new antivirals are being approved against SARS-CoV-2 they suffer from significant constraints and are not indicated for hospitalized patients, who are left with few antiviral options. Repurposed drugs have previously shown controversial clinical results and it remains difficult to understand why certain trials delivered positive results and other trials failed. Our manuscript contributes to explaining the puzzle: this might have been caused by a suboptimal drug exposure and, consequently, an incomplete virus suppression, also because the drugs have mostly been used as add-on monotherapies. As with other viruses (e.g., HIV and HCV) identifying synergistic combinations among such drugs could overcome monotherapy-related limitations. In a cell culture model for SARS-CoV-2 infection the following stringent criteria were adopted to assess drug combinations: 1) identify robust, synergistic antiviral activity with no increase in cytotoxicity, 2) identify the lowest drug concentration inhibiting the virus by 100% (LIC100) and 3) understand whether the LIC100 could be reached in the lung at clinically indicated drug doses. Among several combinations tested, remdesivir with either azithromycin or ivermectin synergistically increased the antiviral activity with no increase in cytotoxicity, improving the therapeutic index and lowering the LIC100 of every one of the drugs to levels that are expected to be achievable and maintained in the lung for a therapeutically relevant period of time. These results are consistent with recent clinical observations showing that intensive care unit admission was significantly delayed by the combination of AZI and RDV, but not by RDV alone, and could have immediate implications for the treatment of hospitalized patients..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop